Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 3/20 | 0.36 |
| ▸ | BACE1 | P56817 | 6/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | CMA1 | P23946 | 1/20 | 0.30 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23705803 | 0.81 | BACE1 (0.34) | PNMTBACE1KDM1ACMA1AHR | |
| SCHEMBL26141014 | 0.78 | HPGD (0.33) | — | |
| SCHEMBL23704964 | 0.77 | BACE1 (0.35) | BACE1KDM1ACMA1AHR | |
| SCHEMBL23705881 | 0.76 | CA12 (0.39) | KDM1A | |
| SCHEMBL23705883 | 0.76 | CA12 (0.39) | KDM1A | |
| SCHEMBL23706069 | 0.76 | CA12 (0.39) | KDM1A | |
| SCHEMBL23705015 | 0.75 | BACE1 (0.35) | BACE1KDM1ACMA1AHR | |
| SCHEMBL23704976 | 0.74 | BACE1 (0.40) | PNMTBACE1KDM1ACMA1AHR | |
| SCHEMBL31367719 | 0.73 | BACE1 (0.40) | PNMTBACE1KDM1ACMA1AHR | |
| SCHEMBL17802089 | 0.71 | SLC6A4 (0.36) | PNMTBACE1KDM1AADRA2ACMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441726-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| EP-4096667-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-115297861-A | Compound and use thereof | 福宏治疗公司 | 2022-11-04 | — | — | CN | disclosed |
| WO-2021155320-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021155320-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441726-B2 | Compounds and uses thereof | VHL, CLN6, TFEB | PNMT 2168/4885BACE1 3015/4885KDM1A 2149/4885 |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | PNMT 2168/4885BACE1 3015/4885KDM1A 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.